ID

34213

Descripción

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01021865

Link

https://clinicaltrials.gov/show/NCT01021865

Palabras clave

  1. 15/1/19 15/1/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

15 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Coronary Artery Disease NCT01021865

Eligibility Coronary Artery Disease NCT01021865

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females
Descripción

ID.1

Tipo de datos

boolean

age 40-60 years
Descripción

ID.2

Tipo de datos

boolean

bmi< or = 35 kg/m2
Descripción

ID.3

Tipo de datos

boolean

diabetic subjects with hba1c concentrations of < or = 8%.
Descripción

ID.4

Tipo de datos

boolean

diabetic subjects will be either on diet and lifestyle therapy alone, or monotherapy with metformin or sulphonylureas (except glyburide).
Descripción

ID.5

Tipo de datos

boolean

all diabetic subjects should be on stable dose oral agent therapy for 3 months prior to enrollment.
Descripción

ID.6

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with cerebrovascular or peripheral vascular disease.
Descripción

ID.7

Tipo de datos

boolean

subjects with suspected or overt autonomic neuropathy.
Descripción

ID.8

Tipo de datos

boolean

diabetic subject on thiazolidinediones, insulin, glp-1 based therapies (exenatide or sitagliptin), alpha-glucosidase inhibitors, glyburide or combination antidiabetic drug therapies.
Descripción

ID.9

Tipo de datos

boolean

diabetics with microalbuminuria.
Descripción

ID.10

Tipo de datos

boolean

Similar models

Eligibility Coronary Artery Disease NCT01021865

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
males and females
boolean
ID.2
Item
age 40-60 years
boolean
ID.3
Item
bmi< or = 35 kg/m2
boolean
ID.4
Item
diabetic subjects with hba1c concentrations of < or = 8%.
boolean
ID.5
Item
diabetic subjects will be either on diet and lifestyle therapy alone, or monotherapy with metformin or sulphonylureas (except glyburide).
boolean
ID.6
Item
all diabetic subjects should be on stable dose oral agent therapy for 3 months prior to enrollment.
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
subjects with cerebrovascular or peripheral vascular disease.
boolean
ID.8
Item
subjects with suspected or overt autonomic neuropathy.
boolean
ID.9
Item
diabetic subject on thiazolidinediones, insulin, glp-1 based therapies (exenatide or sitagliptin), alpha-glucosidase inhibitors, glyburide or combination antidiabetic drug therapies.
boolean
ID.10
Item
diabetics with microalbuminuria.
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial